Sai Life Sciences IPO Details
IPO Date	December 11, 2024 to December 13, 2024
Listing Date	December 18, 2024
Face Value	₹1 per share
Issue Price Band	₹522 to ₹549 per share
Issue Price Final	₹549 per share
Lot Size	27 Shares
Sale Type	Fresh Capital-cum-Offer for Sale
Total Issue Size	5,54,21,123 shares
(aggregating up to ₹3,042.62 Cr)
Fresh Issue	1,73,04,189 shares
(aggregating up to ₹950.00 Cr)
Offer for Sale	3,81,16,934 shares of ₹1
(aggregating up to ₹2,092.62 Cr)
Issue Type	Bookbuilding IPO
Listing At	BSE, NSE
Share Holding Pre Issue	19,06,85,340 shares
Share Holding Post Issue	20,79,89,529 shares
Sai Life Sciences IPO Reservation
Sai Life Sciences IPO offers total 5,54,21,123 shares. Out of which 2,77,10,560 (50.00%) allocated to QIB, 1,10,84,224 (20.00%) allocated to QIB, 83,13,169 (15.00%) allocated to NII, 1,93,97,394 (35.00%) allocated to RII and 1,66,26,336 (30.00%) allocated to Anchor investors.

Investor Category	Shares Offered	Maximum Allottees
QIB Shares Offered	2,77,10,560 (50.00%)	NA
NII (HNI) Shares Offered	83,13,169 (15.00%)	NA
Retail Shares Offered	1,93,97,394 (35.00%)	7,18,422
Total Shares Offered	5,54,21,123 (100.00%)	
Sai Life Sciences IPO Anchor Investors Details
Sai Life Sciences IPO raises ₹912.79 crore from anchor investors. Sai Life Sciences IPO Anchor bid date is December 10, 2024. Sai Life Sciences IPO Anchor Investors list

Bid Date	December 10, 2024
Shares Offered	1,66,26,336
Anchor Portion Size (In Cr.)	912.79
Anchor lock-in period end date for 50% shares (30 Days)	January 14, 2025
Anchor lock-in period end date for remaining shares (90 Days)	March 15, 2025
Sai Life Sciences IPO Timeline (Tentative Schedule)
Sai Life Sciences IPO opens on December 11, 2024, and closes on December 13, 2024.

IPO Open Date	Wed, Dec 11, 2024
IPO Close Date	Fri, Dec 13, 2024
Tentative Allotment	Mon, Dec 16, 2024
Initiation of Refunds	Tue, Dec 17, 2024
Credit of Shares to Demat	Tue, Dec 17, 2024
Tentative Listing Date	Wed, Dec 18, 2024
Cut-off time for UPI mandate confirmation	5 PM on Fri, Dec 13, 2024
Sai Life Sciences IPO Lot Size
Investors can bid for a minimum of 27 shares and in multiples thereof.  The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.

Application	Lots	Shares	Amount
Retail (Min)	1	27	₹14,823
Retail (Max)	13	351	₹1,92,699
S-HNI (Min)	14	378	₹2,07,522
S-HNI (Max)	67	1,809	₹9,93,141
B-HNI (Min)	68	1,836	₹10,07,964
Sai Life Sciences IPO Promoter Holding
The promoters of the company are Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Private Limited, Sunflower Partners, Lily Partners, Marigold Partners and Tulip Partners.
Promoter Holding Pre Issue	40.48%
Promoter Holding Post Issue	35.1%
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue

About Sai Life Sciences Ltd.
Incorporated in January 1999, Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies.

In the Financial Year 2024 and for the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023.The services were offered across countries such as the US, the UK, Europe, and Japan.

The company's business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan.

The company has the following service offerings.

Capabilities in chemistry, manufacturing, and control(“CMC”)/contract development and manufacturing organisations (“CDMO”).
CRO services include integrated discovery (“Discovery”) capabilities across biology, chemistry, drug metabolism and pharmacokinetics
As of September 30, 2024, the company had 2,353 scientific staff, with the majority of the scientific team holding advanced degrees, including 302 Ph. D.s and 1,475 master’s degrees.

As of September 30, 2024, the company had 3135 employees with capabilities across the CRDMO value chain.

Competitive Strength:

As an integrated CRDMO, the company provide a complete platform for discovery, development, and manufacturing.
CRO services include integrated discovery capabilities across biology, chemistry, and drug metabolism and pharmacokinetics.
CDMO platform with a diverse mix of commercial and under-development molecules
Company Financials
Sai Life Sciences Limited Financial Information (Restated Consolidated)
Sai Life Sciences Limited's revenue increased by 20% and profit after tax (PAT) rose by 729% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended	30 Sep 2024	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	2,476.78	2,275.14	2,186.65	2,164.23
Total Income	693.35	1,494.27	1,245.11	897.74
Profit After Tax	28.01	82.81	9.99	6.23
Net Worth	1,044.75	974.34	887.29	877.76
Reserves and Surplus	1,025.44	953.99	867.43	859.17
Total Borrowing	764.49	710.16	699.23	751.32
Amount in ₹ Crore
Key Performance Indicator (KPI)
The market capitalization of Sai Life Sciences IPO is ₹11418.63 Cr.

KPI as of Sun, Mar 31, 2024.

KPI	Values
ROE	11.79%
ROCE	15.96%
RoNW	8.13%
PAT Margin	5.65%
Price to Book Value	10.18
Check Sai Life Sciences IPO Peer Comparison here.
Pre IPO	Post IPO
EPS Rs	4.34	2.69
P/E (x)	126.42	203.82
Note:
The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2024 that is available in RHP.
The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of September 30, 2024 that is available in RHP.
Objects of the Issue (Sai Life Sciences IPO Objectives)
The company propose to utilise the Net Proceeds towards funding the following objects:
Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and
General corporate purposes
Sai Life Sciences IPO Review
[Dilip Davda]  The company is innovation focused CRDMO, NCE, CRO, and CMC entity, and a global player for healthcare related products development serving over 25 world’s leading pharma companies. It marked steady growth in its top lines, but the sudden boost in bottom lines for FY24 raises eyebrows. Based on FY25 annualized earnings, the issue appears aggressively priced. Well-informed/cash surplus/risk seekers may park moderate funds for long term. Read detail review...

Sai Life Sciences IPO Subscription Status (Bidding Detail)
The Sai Life Sciences IPO is subscribed 10.27 times on December 13, 2024 6:19:09 PM (Day 3). The public issue subscribed 1.39 times in the retail category, 29.78 times in the QIB category, and 4.99 times in the NII category. Check Day by Day Subscription Details (Live Status)

Category	Subscription (times)	Shares Offered	Shares bid for
QIB	29.78	1,10,84,225	33,01,25,058
NII	4.99	83,13,168	4,15,22,058
    bNII (bids above ₹10L)	6.1	55,42,113	3,38,13,693
    sNII (bids below ₹10L)	2.78	27,71,056	77,08,365
Retail	1.39	1,93,97,392	2,69,12,493
Total	10.27	3,87,94,785	39,85,59,609
Total Application : 6,46,482

Sai Life Sciences IPO Prospectus
  ›  Sai Life Sciences IPO DRHP
  ›  Sai Life Sciences IPO RHP
  ›  Anchor Investors in Sai Life Sciences IPO
  ›  Sai Life Sciences IPO Final Prospectus
Sai Life Sciences IPO Listing Details
Listing Date	December 18, 2024
BSE Script Code	544306
NSE Symbol	SAILIFE
ISIN	INE570L01029
Final Issue Price	₹549 per share
NSE Listing Group	EQ (Rolling)
BSE Listing Group	B (Rolling)
Pre-Open Session - NSEPre-Open Session - BSE

Listing Day Trading Information
Price Details	NSE SME	NSE SME
Final Issue Price	₹549.00	₹549.00
Open	₹660.00	₹650.00
Low	₹651.20	₹650.00
High	₹787.35	₹780.00
Last Trade	₹765.30	₹764.65